US Stock MarketDetailed Quotes

RNAC Cartesian Therapeutics

Watchlist

20.560
-0.300-1.44%

Trading Nov 7 15:31 ET

491.31MMarket Cap-435P/E (TTM)

Cartesian Therapeutics Stock Forum

Jaguar8

Sep 9 06:32

NEWS

$Cartesian Therapeutics (RNAC.US)$
Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment

Trytosaveabit

Jul 2 05:31

News

$Cartesian Therapeutics (RNAC.US)$ Press Release: Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
Dow Jones· just

Trytosaveabit

Apr 10 15:53

Update! With 2 new 13D

$Cartesian Therapeutics (RNAC.US)$Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Cartesian Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Murat Kalayoglu(19.9%),Seven One Eight Three Four Irrevocable Trust(17.1%), etc.
SEC announcement
13 mins ago
Cartesian Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals...

God(S) is Stonk

Mar 27 13:59

RNAC 👀

$Cartesian Therapeutics (RNAC.US)$ did no one notice springer just bought another 1.9million shares just today 👀, simply does not explain the price action point for this week at all. Eccentric !

God(S) is Stonk

Mar 26 11:19

$Cartesian Therapeutics (RNAC.US)$ FMR had a top position in Viking Therapeutics, and here in Cartesian as well. The reverse split is to allow more institutions to follow suit. If you were to read the paper closely on the pipeline, their RNA cell therapy extends to a suite of autoimmune diseases. With a production up and coming, more partnership might be announced very soon.

God(S) is Stonk

Mar 26 11:15

$Cartesian Therapeutics (RNAC.US)$ there is 50 million shares buy-in (pending) from institutions, CRISPP recently shifted their interest on cell therapy as well, speak volume in the position that Cartesian is in.

God(S) is Stonk

Mar 26 10:38

$Cartesian Therapeutics (RNAC.US)$ Cartesian plans to hold a special meeting of stockholders on March 27, 2024 to seek stockholder approval for the conversion of the Company’s Series A Non-Voting Convertible Preferred Stock into the Company’s common stock and a reverse stock split at a ratio in the range of 1 for 20 and 1 for 30.

Trytosaveabit

Mar 18 17:14

New FORM 4

$Cartesian Therapeutics (RNAC.US)$ 10% Shareholder SPRINGER TIMOTHY A purchased 1.19 million shares of Common Stocks on Mar 14, 15, 2024 at an average price of $0.5618 for a total value of $666.22K.

Trytosaveabit

Mar 5 06:17

Update

$Cartesian Therapeutics (RNAC.US)$ Cartesian Therapeutics Establishes New Corporate Headquarters And MRNA Cell Therapy Manufacturing Facility in Frederick, Maryland

Trytosaveabit

Jan 8 06:28

$Cartesian Therapeutics (RNAC.US)$ Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of MRNA Cell Therapies for Autoimmunity

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data